`
`Application No.
`
`Applicant(s)
`
`16/068,830
`
`Examiner
`
`COFFIN, Robert
`
`Art Unit
`
`AIA (FITF) Status
`
`Yes
`1648
`BAO Q |_|
`
`
`All participants (applicant, applicant’s representative, PTO personnel):
`
`(1) BAD Q. LI.
`
`(2) Melissa L Sistrunk.
`
`Date of Interview: 16 March 2020.
`
`Type:
`
`B Video Conference
`Telephonic
`[:1 Personal [copy given to: Cl applicant
`
`applicant's representative]
`
`Exhibit shown or demonstration conducted: C] Yes
`
`No.
`
`If Yes, brief description:
`
`Others
`CI 103
`CI 102
`CI 112
`C] 101
`Issues Discussed
`(For each of the checked b0x(es) above, please describe below the issue and detailed description of the discussion)
`
`Claim(s) discussed: 1.
`
`Identification of prior art discussed: U89492482.
`
`Substance of Interview
`(For each issue discussed, provide a detailed description and indicate if agreement was reached. Some topics may include: identification or clarification of a reference
`or a portion thereof, claim interpretation, proposed amendments, arguments of any applied references etc...)
`
`See Continuation Sheet.
`
`
`
`Applicant recordation instructions: If is not necessary for applicant to provide a separate record of the substance of interview.
`
`Examiner recordation instructions: Examiners must summarize the substance of any interview of record. A complete and proper recordation of the
`substance of an interview should include the items listed in MPEP 713.04 for complete and proper recordation including the identification of the general
`thrust of each argument or issue discussed, a general indication of any other pertinent matters discussed regarding patentability and the general results or
`outcome of the interview, to include an indication as to whether or not agreement was reached on the issues raised.
`
`[:1 Attachment
`
`/BAO Q LI/
`
`Primary Examiner, Art Unit 1648
`
`U.S. Patent and Trademark Office
`
`PTOL-413B (Rev. 8/11/2010)
`
`Interview Summary
`
`Paper NO- 20200315
`
`
`
`Continuation Sheet (PTOL-413B)
`
`Application No. 16/068,830
`
`Continuation of Substance of Interview including description of the general nature of what was agreed
`to if an agreement was reached, or any other comments: After further searching upon the amendment
`filed by AFCP2.0, a new issue was raised based on the disclosure by US Patent 9492482 and WO
`2010042189A2, which describes an expression vector comprising at least two heterologous molecular
`sequences encoding one or more proteins having the function of an immunomodulator linked to a
`promoter which is activated by said ligand-dependent transcription factor. In one embodiment, the
`immunomodulator is selected from IL-1, IL-2, IL-3, IL-4, IL-5, IL-7, IL-8, IL-9, IL-10R DN or a subunit
`thereof, IL-15, IL-18, IL-21, IL-23, IL-24, IL-27, GM-CSF, IFN-alpha, IFN-gamma, CCL3 (MIP-1a),
`CCL5 (RANTES), CCL7 (MCP3), XCL1 (lymphotactin), CXCL1 (MGSA—alpha), CCR7, CCL19 (MIP-
`3b), CXCL9 (MIG), CXCL10 (IP-10), CXCL12 (SDF-1), CCL21 (6Ckine), OX40L, 4-1BBL, CD40,
`CD70, GITRL, LIGHT, b-Defensin, HMGB1, FIt3L, IFN-beta, TNF-alpha, anADD, TGF-alpha,
`PD-L1RNAi, a PD-L1 antisense oligonucleotide, TGFbRII DN, ICOS-L and 8100. (See section of
`summary, 2nd paragraph). The vectors capable of expressing these biological molecules metionded
`above include human or animal viruses such as vaccinia virus or adenovirus; insect viruses such as
`baculovirus; yeast vectors; bacteriophage vectors (e.g., lambda), and plasmid and cosmid DNA
`vectors, to name but a few. It also teaches that the vector can be (please see section of definitions
`under "vector":). It is noted that all viral vectors are oncolyitc inherently./ In addition, the TD filed on
`March 12 has been noted but it failed to be accepted.
`
`